NEO

T2S&P 1500Russell 2000

NeoGenomics, Inc.

Next est. report 2026-10-28 · AMC

Diagnostics '26: Precision Oncology & Tumor Profiling Genomics '25: Clinical Genomics & Genomics Testing MedTech Long '26: Diagnostics & Early Detection

Loading…

Loading chart…

Overview

NeoGenomics, Inc. specializes in cancer diagnostic and testing services. Its Clinical Services (~93% of revenue) offers advanced tests like NGS, therapy selecti

NeoGenomics, Inc. specializes in cancer diagnostic and testing services. Its Clinical Services (~93% of revenue) offers advanced tests like NGS, therapy selection, and MRD monitoring to hospitals, oncologists, and pathologists. Pharma Services (~7% of revenue) supports pharmaceutical companies and researchers in oncology programs. The company primarily focuses on community settings for patient care.

Key Inputs And Sourcing

1. Direct Lab Labor

Not in registry

labor · United States, Europe, Asia · unknown

Source NeoGenomics employs roughly 2,400 teammates across its global operations. The 'Lab of the Future' initiative aims to drive efficiencies, implying labor is a significant cost.

Confidence: high

2. Reagents and Consumables

Not in registry

component · Global · unknown

Source Essential for all diagnostic testing, including NGS, IHC, FISH, and flow cytometry. The transition of PanTracer LBx to the NovaSeq X platform highlights the use of specific sequencing reagents and consumables.

Confidence: high

3. Instrument Depreciation and Maintenance

Not in registry

other · Global · unknown

Source Investments in 'instrument platform upgrades' and the NovaSeq X platform indicate significant capital expenditure, with associated ongoing depreciation and maintenance costs contributing to COGS.

Confidence: high

4. Freight and Logistics

Not in registry

logistics · containerized-freight-index · Global · unknown

Source Explicitly mentioned as impacting gross margin due to 'higher freight costs and fuel surcharges'.

Confidence: high

5. Software Licenses and IT Services

Not in registry

other · Global · unknown

Source The 'Lab of the Future' initiative includes 'digital pathology, AI-assisted lab automation, our NeoLIMS implementation', indicating significant software and IT-related costs.

Confidence: medium

6. Energy and Utilities

Not in registry

energy · natural-gas · United States, Europe, Asia · unknown

Source Laboratory operations are energy-intensive for equipment, climate control, and general facility needs. While not explicitly detailed as a rising cost, it's a fundamental input.

Confidence: medium

7. Laboratory Facility Costs (Rent/Lease)

Not in registry

other · United States, Europe, Asia · unknown

Source 'Laboratory footprint optimization' and closing 'dry labs' indicate active management of real estate and facility-related expenses.

Confidence: medium

Industry Publications

GenomeWeb (genomeweb.com) — Provides in-depth news and analysis on genomic technologies, molecular diagnostics, and the business of genomics, directly relevant to NeoGenomics' NGS and MRD offerings. Signals to watch include new technology approvals, reimbursement changes, and competitive landscape shifts.
Clinical Laboratory News (www.aacc.org/cln) — Offers insights into clinical laboratory management, regulatory updates, and new testing methodologies, crucial for monitoring operational and compliance aspects of NeoGenomics' diagnostic services. Signals to watch include changes in lab regulations, accreditation standards, and best practices.
Fierce Biotech (fiercebiotech.com) — Covers the biotechnology industry, including drug development, clinical trials, and companion diagnostics, which is relevant for NeoGenomics' Pharma Services division and its role in supporting biopharma partners. Signals to watch include new drug approvals, biomarker discoveries, and pharma partnerships.
CAP Today (www.captodayonline.com) — A publication from the College of American Pathologists, providing news and features on pathology practice, laboratory medicine, and diagnostic testing, directly aligning with NeoGenomics' pathology customer base and services. Signals to watch include updates on pathology guidelines, digital pathology advancements, and laboratory accreditation.
Precision Oncology News (www.precisiononcologynews.com) — Focuses specifically on precision medicine in oncology, including targeted therapies, companion diagnostics, and molecular profiling, which are core to NeoGenomics' business strategy and product portfolio. Signals to watch include breakthroughs in cancer research, new precision oncology treatments, and biomarker utility.

Economic Data Watch

1. FRED — National Health Expenditure Accounts (NHEA)

Not in registryaccess=api

Cadence monthly

Why it matters Overall healthcare spending indicates the market size and health for diagnostic services, directly impacting the addressable market for NeoGenomics.

Signal to watch Increasing expenditures are bullish, decreasing are bearish.

Confidence: low

2. FRED — Consumer Price Index

Not in registryaccess=api

Metric/field CPIMEDSL

Cadence monthly

Why it matters Tracks inflation in medical care services, which can impact NeoGenomics' operating costs and pricing power.

Signal to watch Lower inflation is bullish, higher inflation is bearish.

Confidence: high

3. BLS — Current Employment Statistics (CES)

Matched (medium)lab_headcount · access=api

Metric/field CES6054000001

Cadence monthly

Why it matters Growth in the number of physicians and surgeons indicates a growing base of potential customers and demand for diagnostic services for NeoGenomics.

Signal to watch Increasing employment is bullish, decreasing is bearish.

Confidence: high

4. FRED — Interest Rates

Not in registryaccess=api

Metric/field FEDFUNDS

Cadence monthly

Why it matters Influences the cost of capital for NeoGenomics and its customers (hospitals), affecting investment and expansion decisions.

Signal to watch Stable or decreasing rates are bullish, increasing rates are bearish.

Confidence: high

5. FRED — Gross Domestic Product

Not in registryaccess=api

Metric/field GDP

Cadence quarterly

Why it matters Overall economic growth can indirectly influence healthcare budgets, patient access, and the financial health of NeoGenomics' commercial partners.

Signal to watch Increasing GDP is bullish, decreasing is bearish.

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Registry

Not in registry

Metric/field Study Status, Enrollment

Cadence irregular

Why it matters Indicates ongoing R&D, validation of new assays (e.g., RaDaR ST, PanTracer Family), and potential for future product commercialization and market expansion.

Signal to watch Increase in new trials, positive status changes, or successful completion with results are bullish.

Confidence: high

2. Google Trends — Search Interest

Not in registry

Metric/field Search term volume for 'RaDaR ST' AND 'PanTracer Liquid' AND 'NeoGenomics MRD'

Cadence weekly

Why it matters Reflects public and physician interest and awareness in NeoGenomics' key growth products and advanced diagnostic technologies, signaling potential market adoption.

Signal to watch Increasing search interest is bullish, decreasing is bearish.

Confidence: medium

3. SEC EDGAR — Company Filings

Not in registry

Metric/field 8-K filings (full-text search for 'reimbursement', 'MolDX', 'FDA approval')

Cadence event_driven

Why it matters Provides timely updates on critical regulatory and reimbursement milestones for new products, which are key drivers of future revenue for NeoGenomics.

Signal to watch Filings announcing positive reimbursement decisions or FDA approvals are bullish.

Confidence: high

4. NeoGenomics Careers Page — Job Postings

Not in registry

Metric/field Number of open positions for 'Sales Specialist', 'Oncology', 'Pathology', 'R&D'

Cadence weekly

Why it matters Indicates investment in commercial expansion (sales force) and R&D pipeline, aligning with management's stated growth strategies.

Signal to watch Increasing job postings in key growth areas are bullish.

Confidence: medium

5. USPTO PatentsView — Patent Grants/Applications

Not in registry

Metric/field Patent activity by assignee 'NeoGenomics'

Cadence irregular

Why it matters Tracks innovation and intellectual property development, which can provide a competitive moat and support future product launches.

Signal to watch Increase in new patent applications or grants related to oncology diagnostics is bullish.

Confidence: high

Paid Alt Data Watch

1. IQVIA — Medical Claims Data

Matchediqvia_medical_claims · access=file · map_only

Metric/field CPT code utilization for molecular diagnostic tests (e.g., specific codes for liquid biopsy, MRD, NGS panels)

Cadence monthly

Why it matters Provides granular, independent data on actual test utilization, market share, and reimbursement trends for NeoGenomics' products and the broader oncology diagnostics market.

Signal to watch Increasing utilization of relevant CPT codes for NeoGenomics' tests is bullish.

Confidence: high

2. Truveta — EHR Data

Matched (medium)truveta_ehr_clinical_records · access=file · map_only

Metric/field De-identified patient data for oncology diagnostic test orders and results (e.g., NGS, MRD, therapy selection)

Cadence daily

Why it matters Offers real-time insights into physician ordering patterns, adoption rates of new tests, and patient outcomes, which can validate NeoGenomics' commercial traction.

Signal to watch Increasing order volumes for NeoGenomics' key tests (RaDaR ST, PanTracer Family) or related biomarkers are bullish.

Confidence: high

3. Similarweb — Web Traffic & Engagement

Matchedsimilarweb_website_traffic_engagement · access=file · map_only

Metric/field Website traffic (neogenomics.com) and engagement metrics (e.g., unique visitors, bounce rate, time on site) for healthcare professional sections

Cadence monthly

Why it matters Provides a proxy for digital engagement from healthcare professionals and potential customers, indicating interest in NeoGenomics' offerings.

Signal to watch Increasing traffic and engagement, particularly to product-specific pages, are bullish.

Confidence: high

4. Definitive Healthcare — PhysicianView

Not in registry

Metric/field Oncologist and pathologist prescribing/ordering patterns for molecular diagnostic tests, referral networks

Cadence monthly

Why it matters Offers insights into physician adoption, competitive dynamics, and the effectiveness of NeoGenomics' commercial strategy in the community setting.

Signal to watch Increasing adoption by target oncologists and pathologists is bullish.

Confidence: high

5. GlobalData Healthcare — Market Research Reports

Matchedglobaldata_healthcare_healthcare_forecasts_market_sizing · access=file · map_only

Metric/field Market size and growth forecasts for oncology diagnostics, liquid biopsy, and MRD testing segments

Cadence irregular

Why it matters Provides independent validation of the total addressable market and growth trajectory for NeoGenomics' strategic focus areas, informing long-term outlook.

Signal to watch Upward revisions in market size or growth forecasts are bullish.

Confidence: high

Search Keywords Brand Product

RaDaR ST
PanTracer Family
PanTracer Liquid
PanTracer Pro
PTEN companion diagnostic
AML MRD Flow assay
NeoTYPE
HemeFISH
oncology diagnostics
cancer testing services
next-generation sequencing
NGS
molecular residual disease
MRD testing
therapy selection
hematology diagnostics
solid tumor testing
liquid biopsy
digital pathology
lab automation
companion diagnostics

Search Keywords Event Phrases

NeoGenomics earnings
NeoGenomics Q2 2026 results
RaDaR ST MolDX approval

Search Keywords Policy Regulatory

MolDX reimbursement
Medicare coverage diagnostics
FDA approval diagnostics

What They Do (Plain English & Analogies): NeoGenomics is like a specialized detective agency for cancer. Instead of solving crimes, they analyze tiny clues from a patient's body, like blood or tissue samples, to figure out exactly what kind of cancer they have, how aggressive it is, and which treatments might work best. They offer a wide range of advanced tests, from looking at chromosomes and genes to identifying specific proteins, helping doctors make personalized treatment plans. They also work with pharmaceutical companies, acting as a research partner to help them develop new cancer drugs and understand how existing ones work. Their main focus is on supporting community hospitals and oncologists, bringing cutting-edge cancer diagnostics closer to where most patients receive care. They are leveraging their leadership in blood cancer diagnostics to expand their offerings for solid tumors, including tests to help select the right therapy and monitor for any remaining cancer after treatment.
Very Brief History: NeoGenomics, Inc. was founded in Fort Myers, Florida, in 2001 as a specialized cancer genetics laboratory. The company expanded its capabilities, launching its sequencing platform in 2013 and acquiring Clarient, Inc. in 2015 to broaden its diagnostic offerings. It has since grown its laboratory network across the United States and established an international presence, particularly in pharma services. The company acquired Pathline in 2025, strengthening its Northeast presence.
"Street Stereotype": NeoGenomics is generally perceived as a pure-play oncology solutions company with a strong heritage in hematology and a leading market share in community settings. Investors and analysts often view it as differentiated from larger reference labs due to its deep and broad portfolio and relentless focus on community practices. The company is seen as a growth story, leveraging its next-generation sequencing (NGS) and re-entering the molecular residual disease (MRD) market, with expectations for consistent double-digit revenue growth.
Subsidiaries On Linked In*: Clarient, Inc. — Acquired in 2015; LinkedIn: Clarient, a GE Healthcare Company
Clarient Diagnostic Services, Inc. — Subsidiary of Clarient, Inc., acquired in 2015
Pathline — Acquired in 2025, strengthened Northeast presence; exited low-margin non-oncology business acquired from Pathline in Q2 2026.; LinkedIn: Pathline Pathology
Customer Sectors & Example Clients: NeoGenomics serves a diverse range of customers within the healthcare and pharmaceutical sectors. Their primary customer sectors include hospitals, reference laboratories, pathologists, oncologists, clinicians, academic medical centers, pharmaceutical companies, and researchers. They specifically focus on community hospitals and community oncologists, where approximately 80% of patients seek cancer treatment. For pharmaceutical clients, they support oncology programs from discovery to commercialization, acting as a partner for biomarker testing, clinical trial support, and companion diagnostics. A specific client mentioned is AstraZeneca, in relation to their newly approved TRUQAP drug.
New Customers / Segments They'Re Targeting: NeoGenomics is actively targeting new segments within oncology, particularly expanding its offerings for solid tumors in the large, underpenetrated markets of therapy selection and molecular residual disease (MRD). They are also reaching into urologic oncology, a new setting for them, with the launch of PTEN, an FDA-approved immunohistochemistry companion diagnostic for prostate cancer. Their commercial team has been reorganized into two dedicated ecosystems, one focused on oncology and one on pathology, to sharpen accountability and scale for growth.
Sales Geographies And Expansion Plans: NeoGenomics primarily sells its clinical diagnostic services within the United States, where its laboratory network and customer base are centered. They have a strong presence in the Northeast, which has seen growth at 1.5 times their national average. The company also has an international reach, particularly in its pharma services division, with a CAP-accredited full-service sample-processing laboratory in Cambridge, England, United Kingdom. Management plans to expand its clinical commercial organization, aiming to exceed 160 commercial representatives during the third quarter of 2026, and will continue to assess the size of the commercial organization based on market penetration rates and reimbursement wins. They also expect benefits from Epic Aura integrations to begin in 2027, strengthening their differentiation and driving higher test adoption per site.
How Key Themes May Help/Hurt: The 'MedTech Long '26: Diagnostics & Early Detection' theme strongly benefits NeoGenomics. The accelerating technological advancements in genomics and multiomics directly align with NeoGenomics' focus on next-generation sequencing (NGS), therapy selection (PanTracer Family), and molecular residual disease (MRD) testing (RaDaR ST). The increasing global prevalence of cancer and an aging population create a sustained demand for advanced diagnostic solutions, which NeoGenomics provides. Favorable regulatory developments, such as MolDX reimbursement decisions for RaDaR ST indications, enhance market access and accelerate adoption of their novel assays. Their pipeline investment in next-generation whole genome sequencing MRD assays further positions them to capitalize on these trends. However, persistent reimbursement pressures and evolving payer policies, particularly for novel tests like MRD, could impact profitability and market uptake if coverage is delayed or rates are unfavorable. Intensifying competition from both established players and new entrants in the diagnostics and early detection space could also lead to pricing pressures and increased commercialization costs, potentially impacting margins.

3 Main Long-Term Bull Details

Portfolio Transformation and High-Growth Market Penetration: NeoGenomics is strategically transforming its portfolio to focus on high-growth areas like therapy selection and molecular residual disease (MRD), which represent large, underpenetrated market opportunities ($33 billion combined). The strong performance of its NGS business, growing at 26% year-over-year and now representing one-third of clinical revenue, demonstrates successful execution in these areas, with new products like the PanTracer Family and RaDaR ST driving growth and 'halo effects' across the portfolio.
Community Setting Leadership and Commercial Strategy: The company enjoys a leading 25% market share across hematology diagnostics and therapy selection, leveraging this trusted position to expand its broader portfolio in the community setting, where approximately 80% of patients seek treatment. Its effective commercial strategy, including a broad test menu, fast turnaround times, deep payer coverage, EHR integration (Epic Aura), and a reorganized commercial team focused on oncology and pathology, is designed to reduce friction and drive adoption, leading to durable and profitable growth.
Operational Efficiency and Pipeline Innovation: NeoGenomics is focused on driving consistent double-digit revenue growth while improving profitability through its 'Lab of the Future' initiative, which spans digital pathology, AI-assisted lab automation, instrument upgrades (like NovaSeq X for PanTracer LBx), and laboratory footprint optimization, contributing to significant gross margin expansion. Concurrently, the company continues to invest in its pipeline, with a next-generation whole genome sequencing MRD assay on track for data generation in 2027 and potential clinical launch in 2029, ensuring sustained growth beyond current offerings.

3 Main Long-Term Bear Details

Nonclinical Business Headwinds and Revenue Drag: The nonclinical (Pharma) business continues to face headwinds, with revenue declining 26% year-over-year in Q2 2026 and accounting for roughly 5% of total revenue. While bookings are increasing, the pull-through rate has been lower than expected, leading to adjusted full-year expectations for this segment to be down high single digits. Continued softness or slower-than-anticipated recovery in this segment could be a drag on overall revenue growth and profitability.
Reimbursement and Payer Coverage Challenges for New Products: While MolDX reimbursement for some RaDaR ST indications and PanTracer LBx is positive, securing meaningful private payer rates for these novel, high-value tests is a lengthy process. Delays or unfavorable coverage decisions from commercial payers could impact the profitability and broad market uptake of key growth drivers like RaDaR ST, where reimbursement decisions are 'key to driving future revenue'.
Execution Risks in Scaling New Products and Operations: The company faces execution risks in rapidly scaling new product launches like RaDaR ST and the PanTracer Family to meet ambitious growth targets, especially with planned sales force expansion and the transition of assays to new platforms like NovaSeq X. While the 'Lab of the Future' aims for efficiencies, successful implementation across multiple initiatives is complex and critical for achieving targeted gross margin expansion.

Competitors And Differentiation: NeoGenomics competes with other diagnostic companies, including larger reference labs and pure-play NGS providers. Their differentiation stems from several factors: a broad test menu covering various modalities; a leading 25% market share across hematology diagnostics and therapy selection, which serves as a trusted foundation; a deep focus on the community setting where 80% of patients seek treatment; strong workflow integration and customer experience (evidenced by a Net Promoter Score in the high 70s and Epic Aura integrations); and unique capabilities and a menu that other pure-play NGS providers do not possess, particularly with highly competitive products like the PanTracer Family and RaDaR ST (e.g., RaDaR ST detects down to 1 part per million).
Recent Performance & What The Market'S Focused On: NeoGenomics reported strong Q2 2026 results, with total revenue up 11% year-over-year to $201.7 million, exceeding guidance. Clinical revenue grew a robust 14%, driven by a 2% increase in test volumes and a 12% increase in Average Unit Price (AUP). Next-Generation Sequencing (NGS) revenue was particularly strong, growing 26% year-over-year and comprising one-third of clinical revenue. Adjusted gross margin expanded by 260 basis points year-over-year, and adjusted EBITDA grew 36%. The company raised its full-year 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA guidance to $56 million to $58 million. The market is focused on the continued strong and durable growth of the clinical and NGS businesses, the successful expansion into high-value MRD and therapy selection markets (especially MolDX reimbursement decisions for RaDaR ST), and the realization of operational efficiencies from the 'Lab of the Future' initiative driving margin expansion. Persistent weakness in the nonclinical (pharma) business remains a point of concern, though management is committed to its return to growth in 2027. The sustainability of AUP growth and the mix shift towards higher-value testing are also closely watched.

Revenue Segments And Estimated Mix: Clinical Services — Mix: ~92.8% (Q2 2026); Source: Q2 2026 earnings transcript; Trend: Grew 14% year-over-year. NGS business grew 26% year-over-year and comprises ~1/3 of clinical revenue. Driven by 2% volume increase and 12% AUP increase.
Nonclinical Business (Pharma Services/Oncology Data Solutions) — Mix: ~7.2% (Q2 2026); Source: Q2 2026 earnings transcript; Trend: Declined 15% year-over-year to $14.5 million. Pharma revenue declined 26%, partially offset by 17% growth in Oncology Data Solutions. Expected to be down high single digits year-over-year for FY2026.
Product Brands: RaDaR ST
PanTracer Family
PanTracer Liquid
PanTracer Pro
PTEN
AML MRD Flow assay
NeoTYPE
HemeFISH
Paletrra
NEO PanTracer Tissue
NEO PanTracer Tissue + HRD
AML NanoMRD

Bull / Bear Details

NeoGenomics is a compelling long in oncology diagnostics, demonstrating durable double-digit clinical and NGS revenue growth, driven by successful expansion int

Thesis

NeoGenomics is a compelling long in oncology diagnostics, demonstrating durable double-digit clinical and NGS revenue growth, driven by successful expansion into high-value MRD and therapy selection markets. Operational efficiencies and a strengthened capital structure support margin expansion. However, investor sentiment remains cautious due to persistent nonclinical business weakness and recent leadership transitions, despite strong Q2 2026 results and raised full-year guidance. (October 17, 2026)

Bull case

NeoGenomics continues to deliver robust and durable clinical revenue growth, with NGS revenue expanding at a strong 26% year-over-year in Q2 2026. This performance, driven by a favorable mix shift towards high-value testing and a 12% AUP increase, significantly outpaces the market and has led to raised full-year 2026 guidance for NGS to the mid-20s.
The company is strategically expanding into large, underpenetrated markets, including the $20 billion MRD market with RaDaR ST and the $13 billion therapy selection market with the PanTracer Family. With 3 additional RaDaR ST indications pending MolDX approval, potentially covering over 40% of the market, and new product launches like PTEN, NeoGenomics is well-positioned for future growth.
Operational efficiencies from the 'Lab of the Future' initiative are driving significant margin expansion, with adjusted gross margin up 260 basis points year-over-year in Q2 2026. The successful refinancing of convertible debt, extending maturity to 2032, strengthens the capital structure, while a reorganized commercial team and EHR integrations enhance market access.

Bear case

The nonclinical (pharma) business remains a drag on overall performance, experiencing a 15% year-over-year decline in Q2 2026 and a 26% decline in pharma revenue specifically. Despite Q2 bookings being at "all-time highs," the segment continues to face headwinds, leading to adjusted full-year expectations for this segment to be down high single digits.
Investor confidence has been impacted by recent leadership transitions, with the stock plunging over 12% on October 6, 2026, following the announcement of a new CEO effective January 2027. Concerns about the company's ongoing unprofitability, despite preliminary Q3 revenue beating consensus, highlight a cautious market sentiment.
Securing broad private payer reimbursement for new high-value tests like RaDaR ST and PanTracer Liquid remains a lengthy and challenging process. While MolDX approvals are progressing, the time required to build commercial coverage could delay full revenue realization and broad market penetration for these key growth drivers, impacting profitability.

Bull / Bear Case

Bear Case: The nonclinical (pharma) business remains a significant drag on overall performance, experiencing a 15% year-over-year decline in Q2 2026 and a 26% decline in pharma revenue specifically. Despite Q2 bookings being at "all-time highs," the segment continues to face headwinds, leading to adjusted full-year expectations for this segment to be down high single digits. Securing broad private payer reimbursement for new high-value tests like RaDaR ST and PanTracer Liquid remains a lengthy and challenging process. While MolDX approvals are progressing, the time required to build commercial coverage could delay full revenue realization and broad market penetration for these key growth drivers, impacting profitability. Investor confidence has been impacted by recent leadership transitions, with the stock plunging over 12% on October 6, 2026, following the announcement of a new CEO effective January 2027, despite preliminary Q3 revenue beating consensus. The company remains unprofitable with a negative P/E ratio, and its EV/EBITDA of 98.80 (LTM) or 36.7x (2026 estimate) appears stretched given the persistent unprofitability and execution risks.
Bull Case: NeoGenomics demonstrates robust and durable clinical revenue growth, with NGS revenue expanding at a strong 26% year-over-year in Q2 2026 and preliminary Q3 showing 28% growth, significantly outpacing the market. This performance is driven by a favorable mix shift towards high-value testing and a 12% AUP increase. The company is strategically expanding into large, underpenetrated markets like MRD ($20 billion) with RaDaR ST and therapy selection ($13 billion) with the PanTracer Family. With 3 additional RaDaR ST indications pending MolDX approval, potentially covering over 40% of the market, and new product launches like PTEN, NeoGenomics is well-positioned for future growth. Operational efficiencies from the 'Lab of the Future' initiative are driving significant margin expansion, with adjusted gross margin up 260 basis points year-over-year in Q2 2026. The successful refinancing of convertible debt strengthens the capital structure, while a reorganized commercial team and EHR integrations enhance market access.
More Compelling & Why: I find the Bear Case more compelling. While NeoGenomics shows strong clinical and NGS growth, its current valuation, particularly the negative P/E ratio and high EV/EBITDA (98.80 LTM, 36.7x 2026e), appears stretched given the persistent unprofitability and the drag from the declining nonclinical business. The single strongest argument for the bear case is the significant execution risk and lengthy timeline for securing broad private payer reimbursement for new, high-value tests like RaDaR ST, which is critical for future revenue and profitability. My view would flip to bullish if the company demonstrates a clear path to sustained profitability, evidenced by positive GAAP earnings per share, and a significant acceleration in private payer coverage for its new high-value tests, leading to a more reasonable EV/EBITDA multiple.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
NGS Revenue Growth Rate	Next-Generation Sequencing (NGS) is NeoGenomics' high-value, high-growth segment, driving overall clinical revenue and Average Unit Price (AUP) expansion. Continued strong performance validates the company's portfolio transformation strategy and market penetration.	Year-over-year NGS revenue growth in Q3 and Q4 2026. Management raised full-year 2026 NGS guidance to 'mid-20s' percent growth, following 26% growth in Q1 and Q2 2026.	NGS revenue growth consistently at or above mid-20s percent year-over-year = bullish; Deceleration below mid-20s percent = bearish.	Company earnings reports and calls for Q3 and Q4 2026.	[]	[]
MolDX Reimbursement Decisions for RaDaR ST Indications	MolDX coverage is critical for expanding market access and driving future revenue for RaDaR ST, a key growth driver in the underpenetrated molecular residual disease (MRD) market. Successful approvals will significantly increase the addressable market.	Announcement of MolDX coverage for the 2 additional RaDaR ST indications submitted prior to Q2 2026, and the 1 new indication submitted in Q2 2026. Management anticipates decisions for the first two by year-end 2026, and the third in H1 2027. If all 5 indications are approved, NeoGenomics would have access to over 40% of the total addressable market for tumor-informed MRD testing.	Approval for the 2 additional indications by year-end 2026 = bullish; Approval for the third indication in H1 2027 = bullish; Delays or rejection = bearish.	Company press releases, SEC filings (10-Q, 8-K), and earnings calls.	[]	[]
Pharma Business Bookings and 2027 Growth Outlook	While the nonclinical (Pharma) business is a small portion of total revenue, its persistent decline has been a bear point. Signs of stabilization or sequential growth, driven by strong bookings, would validate the turnaround strategy and alleviate investor concerns about this segment.	Management commentary on Q3 and Q4 2026 earnings calls regarding continued pharma bookings momentum and confidence in achieving year-over-year growth for the nonclinical segment in 2027. Q2 2026 bookings were reported as 'all-time highs'.	Continued 'all-time high' bookings or strong sequential growth in bookings = bullish for 2027 outlook; Stagnation or decline in bookings = bearish for 2027 outlook.	Company earnings reports and calls for Q3 and Q4 2026.	[]	[]
Clinical Business Volume Growth (Excluding Low-Value Contract Impact)	This factor provides a clearer picture of underlying demand for NeoGenomics' core clinical services, especially as the company strategically shifts towards higher-value testing and laps the impact of an exited low-value contract.	Management commentary on the Q3 2026 earnings call regarding clinical volume growth, specifically addressing the impact of lapping the high-volume, low-value contract exited in Q4 2025. Expected Q3 volume growth is projected to be about 1-1.5%.	Clinical volume growth (adjusted for the exited contract) exceeding mid-single digits = bullish; Volume growth at or below 1-1.5% in Q3 without clear explanation of low-value contract impact = bearish.	Company earnings reports and calls for Q3 2026.	[]	[]
Lab of the Future Initiatives and Gross Margin Expansion	Operational efficiencies from the 'Lab of the Future' initiative are crucial for driving profitability and achieving the company's margin expansion goals, strengthening the investment thesis. This includes automation, digital pathology, and instrument upgrades like NovaSeq X.	Management commentary on Q3 and Q4 2026 earnings calls regarding progress on Lab of the Future initiatives and their contribution to gross margin improvement. The full-year 2026 adjusted gross margin improvement target is 100-150 basis points. The NovaSeq X transition for heme is expected to yield benefits in late 2027.	Gross margin expansion consistently within or exceeding the 100-150 basis points target = bullish; Failure to meet margin expansion targets or delays in initiative benefits = bearish.	Company earnings reports and calls for Q3 and Q4 2026.	[]	[]

Key Reported Metrics, Reratings Triggers & Results6 rows

As the largest segment, representing approximately 93% of total revenue, its robust growth is fundamental to the company's overall financial performance and val

Upcoming print · 2026-10-27

Key reported metrics			Rerating thresholds
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date
Clinical Revenue Growth	14%	As the largest segment, representing approximately 93% of total revenue, its robust growth is fundamental to the company's overall financial performance and validates its strategic focus on community oncology.	For the stock to rerate higher, NeoGenomics' Clinical Revenue Growth for Q3 2026 needs to be reported at or above 16% year-over-year, demonstrating acceleration from Q2's 14% and exceeding the 'low teens' full-year guidance. Additionally, the company must formally raise its full-year 2026 clinical revenue growth guidance to the mid-to-high teens, building on the anticipated increase to total revenue guidance.	Exceeding prior clinical revenue growth and raising full-year guidance would validate NeoGenomics' strategic focus on high-value oncology diagnostics and market penetration. This signals durable growth, strengthens its competitive position, and boosts investor confidence in long-term profitability.	2026-10-28
Nonclinical Business Revenue Growth	-15%	Despite its small contribution to total revenue, the persistent decline in this segment is a key concern for investors. Signs of stabilization and progress towards the 2027 growth target are crucial for overall sentiment.	For the stock to re-rate higher, NeoGenomics' Nonclinical Business Revenue Growth for Q3 2026 needs to show a significant improvement from the -15% year-over-year decline reported in Q2 2026. Specifically, a decline in the high single-digit percentage range (e.g., -9% to -5% year-over-year) or better, would signal stabilization and progress towards the company's commitment to achieving year-over-year growth in 2027.	Hitting this threshold would demonstrate that the nonclinical segment is stabilizing and on a clear path to recovery, alleviating a key bear point for investors. This would improve overall revenue growth visibility, validate management's turnaround strategy for this segment, and enhance investor confidence in NeoGenomics' long-term profitability and competitive position.	2026-10-28
NGS Revenue Growth	26%	This high-value segment is the primary driver of overall clinical revenue and Average Unit Price (AUP) expansion. Sustained strong growth validates the company's portfolio transformation and market penetration strategy in oncology diagnostics.	For NeoGenomics to rerate higher, NGS Revenue Growth for Q3 2026 needs to be reported at or above 29% year-over-year, exceeding the preliminary 28% announced. Additionally, the company would need to significantly raise its full-year 2026 NGS revenue growth guidance to the high-20s or low-30s percent range, demonstrating sustained acceleration and confidence beyond current 'mid-20s' expectations.	Exceeding the already strong preliminary NGS growth and raising full-year guidance would validate NeoGenomics' portfolio transformation and market penetration in high-value oncology diagnostics. This signals durable growth, strengthens its competitive position, and helps alleviate investor concerns regarding leadership changes and nonclinical business headwinds, driving a positive rerating.	2026-10-28
Adjusted Gross Margin Growth	6.88%	Gross margin expansion is a key focus area for the company, driven by AUP growth and efficiency initiatives. Continued improvement signals successful execution of their profitability strategy.	NeoGenomics needs to report year-over-year Adjusted Gross Margin Growth (expansion) of at least 150 basis points in Q3 2026. This would demonstrate continued momentum from the 260 basis points expansion seen in Q2 2026 and indicate strong progress towards or exceeding the full-year 2026 target of 100-150 basis points of improvement.	Continued strong adjusted gross margin expansion validates the success of 'Lab of the Future' initiatives and favorable average unit price (AUP) growth, which are critical components of NeoGenomics' profitability strategy. Exceeding expectations signals sustainable operational efficiency and strengthens the investment thesis, driving a positive rerating.	2026-10-27
Nonclinical Business Revenue Growth	-15%	While a small portion of total revenue, its persistent decline is a bear point. Investors will watch for signs of stabilization or sequential growth to validate the turnaround strategy.	For the stock to re-rate higher, NeoGenomics' Nonclinical Business Revenue Growth for Q3 2026 needs to show a significant improvement from the -15% year-over-year decline reported in Q2 2026. Specifically, a decline in the high single-digit percentage range (e.g., -9% to -5% year-over-year) or better, would signal stabilization and progress towards the company's commitment to achieving year-over-year growth in 2027.	Hitting this threshold would demonstrate that the nonclinical segment is stabilizing and on a clear path to recovery, alleviating a key bear point for investors. This would improve overall revenue growth visibility, validate management's turnaround strategy for this segment, and enhance investor confidence in NeoGenomics' long-term profitability and competitive position.	2026-10-28
NGS Revenue Growth	26%	This is the high-value, high-growth segment, driving overall clinical revenue and AUP expansion. Continued strong performance validates their portfolio transformation strategy.	For NeoGenomics to rerate higher, NGS Revenue Growth for Q3 2026 needs to be reported at or above 29% year-over-year, exceeding the preliminary 28% announced. Additionally, the company would need to significantly raise its full-year 2026 NGS revenue growth guidance to the high-20s or low-30s percent range, demonstrating sustained acceleration and confidence beyond current 'mid-20s' expectations.	Exceeding the already strong preliminary NGS growth and raising full-year guidance would validate NeoGenomics' portfolio transformation and market penetration in high-value oncology diagnostics. This signals durable growth, strengthens its competitive position, and helps alleviate investor concerns regarding leadership changes and nonclinical business headwinds, driving a positive rerating.	2026-10-28

Last reported · 2026-07-28

Key reported metrics
Metric	Last period	Why it matters
Average Unit Price (AUP) Growth	8%	AUP growth reflects the company's ability to monetize its high-value test portfolio and improve profitability through strategic pricing and payer negotiations, directly impacting gross margins and overall financial health.
Clinical Business Revenue Growth	14%	Clinical business revenue growth is the core indicator of NeoGenomics' market penetration and execution in oncology diagnostics. Sustained double-digit growth is essential for their overall financial performance and investment thesis.
NGS Revenue Growth	26%	NGS revenue growth is critical as it represents NeoGenomics' high-value, high-growth segment, driving overall clinical revenue and AUP expansion. Continued strong performance validates their portfolio transformation strategy.

Key Questions

Will NeoGenomics sustain its strong NGS revenue growth, which was 26% year-over-year in Q2 2026, and achieve its raised full-year 2026 guidance of mid-20s perce

Will NeoGenomics sustain its strong NGS revenue growth, which was 26% year-over-year in Q2 2026, and achieve its raised full-year 2026 guidance of mid-20s percent growth, particularly as clinical volume growth is anticipated to be lower in Q3 due to the exited low-value contract?

Question 2: With two RaDaR ST indications currently reimbursed by MolDX and three additional indications pending, will NeoGenomics secure the anticipated MolDX approvals for the two indications by year-end 2026 and the third in H1 2027, and will these approvals effectively accelerate RaDaR ST adoption and revenue contribution?
Question 3: Can NeoGenomics continue to drive significant gross margin expansion, building on the 260 basis points year-over-year improvement in Q2 2026, to meet its full-year 2026 target of 100-150 basis points, while also demonstrating tangible progress towards returning its nonclinical (pharma) business to year-over-year growth in 2027 following its revised high single-digit decline expectation for 2026?

Earnings Transcript Summary2 rows

2026-07-28 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Driving durable and profitable growth: Management emphasized consistent results, exceeding revenue guidance, and raising full-year guidance, particularly driven by the clinical business and NGS. 2. Expanding into high-value, underpenetrated markets: Focus on therapy selection (PanTracer Family) and MRD (RaDaR ST) to leverage their hematology leadership and drive growth in solid tumor offerings, with efforts to secure reimbursement for RaDaR ST. 3. Operational efficiency and margin expansion: Initiatives like 'Lab of the Future' (automation, digital pathology, instrument upgrades) and G&A expense discipline are key to improving gross margins and adjusted EBITDA.	Call Takeaway & ToneThe overall takeaway from the call was highly positive and confident. NeoGenomics delivered strong second-quarter results, exceeding revenue guidance, driven by robust clinical and NGS growth. Management expressed confidence in the durability of their NGS business and their strategy to expand into high-value therapy selection and MRD markets. Efforts in operational efficiency and margin expansion were highlighted as yielding results, leading to a raised full-year guidance. Despite continued weakness in the nonclinical pharma business, management was optimistic about its future recovery and its strategic value. The tone was upbeat, emphasizing consistent execution and a strong outlook for continued profitable growth.	Prior Quarter'S Y/Y Growth By SegmentTotal revenue: 11% year-over-year growth (Q1 2026). Clinical business revenue: 14% year-over-year growth (Q1 2026). NGS revenue: 26% year-over-year growth (Q1 2026). Nonclinical business revenue: 15% year-over-year decline (Q1 2026). Pharma business revenue: Not explicitly detailed for Q1 2026, but contributed to the nonclinical decline. Oncology Data Solutions (ODS) business revenue: Not explicitly detailed for Q1 2026.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. NGS growth sustainability: Analysts questioned if the 26% NGS growth was sustainable given potential tough comparisons in the back half of the year. Management responded that they view their NGS position as very durable, citing 14% volume growth and 12% AUP growth (2/3 from mix shift) in Q2, and raised the full-year NGS guidance to mid-20s. 2. Nonclinical (Pharma) business performance and strategic importance: Analysts pressed on the continued decline in the nonclinical pharma business and its overall importance given its small revenue contribution. Management acknowledged underperformance but highlighted significant increases in Q2 bookings, reiterating its value for early market access, R&D leverage, and alignment with their emerging portfolio, while noting its minimal impact on overall business due to its small size. 3. AUP growth sustainability and future volume/AUP mix: Analysts inquired about the sustainability of the strong 12% AUP growth and the expected mix of AUP versus volume growth in upcoming quarters. Management stated AUP growth is durable, driven by RCM initiatives (managed care pricing gains) and a continuous mix shift towards high-value NGS testing. They expect AUP-led growth in Q3 and Q4, with volume growth around 1-1.5% in Q3 due to lapping a low-value contract exit, and a shift towards mid-single-digit volume growth and softer AUP growth in 2027.	Revenue SegmentsTotal revenue: 11% year-over-year growth. Clinical business revenue: 14% year-over-year growth. NGS revenue: 26% year-over-year growth. Nonclinical business revenue: 15% year-over-year decline. Pharma business revenue: 26% year-over-year decline. Oncology Data Solutions (ODS) business revenue: 17% year-over-year growth.

2026-04-28 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Driving consistent double-digit revenue growth: Management highlighted 11% total revenue growth and 14% clinical revenue growth in Q1 2026, exceeding guidance, and reiterated their belief in delivering consistent double-digit revenue growth. They are particularly focused on NGS, which grew 26% year-over-year and represents about one-third of clinical revenue. 2. Portfolio transformation and expansion into high-growth markets (Therapy Selection & MRD): The company is purposefully transforming its portfolio with new product launches like RaDaR ST (re-entering the $20 billion MRD market) and the PanTracer Family (addressing the $13 billion therapy selection market). They are focused on driving adoption of these new high-value tests and expanding into new indications. 3. Winning in the community setting and improving Average Unit Price (AUP): Management emphasized their strategy to be a partner of choice in the community setting, where 80% of patients seek treatment. They are focused on commercial strategy execution, which led to 8% year-over-year AUP growth, driven by the mix shift towards high-value NGS testing and RCM initiatives.	Call Takeaway & ToneThe overall takeaway from the call is that NeoGenomics delivered strong first-quarter results, exceeding revenue guidance, driven by robust clinical and NGS growth, and is confident in its strategic direction and future growth drivers. The tone was optimistic and confident, with management highlighting successful product launches (RaDaR ST, PanTracer Liquid), strong execution in the community setting, and a positive outlook for continued double-digit revenue growth and margin expansion, despite acknowledging some headwinds in the nonclinical business and the impact of exiting low-value contracts.	Prior Quarter'S Y/Y Growth By SegmentTotal revenue: 11% (Q4 2025). Clinical revenue: 16% (Q4 2025). NGS revenue: 23% (Q4 2025). Nonclinical business revenue: Declined by over 25% (Q4 2025).	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Sustainability of NGS growth and AUP trends: Analysts questioned if the robust NGS growth (26% y/y) and AUP increase (8% y/y) were sustainable given difficult comps. Management responded that they feel very good about sustainability, citing early positive signs from PanTracer LBx and PanTracer Pro, and that AUP is sustainable, driven about half by NGS mix shift and half by RCM initiatives and price increases across all modalities. 2. Guidance raise and conservatism: An analyst asked why management raised guidance rather than 'banking the beat' and sought comfort that the revised guidance was still conservative. Management explained they maintain a philosophy of high confidence in their guide, seeing potential upside from PanTracer LBx adoption, better uptake of RaDaR ST, and a slowing decline in the nonclinical business, suggesting more opportunity than downside. 3. Impact of Pathline and low-value contract on volume growth: Analysts inquired about the impact of lapping the Pathline acquisition and exiting a high-volume, low-value contract on future volume growth. Management clarified that while overall Q2 volume growth is expected to be flattish year-over-year due to absorbing the exit of the low-value contract, they expect sequential volume growth from Q2 onwards. They highlighted the strategic benefit of Pathline in the Northeast, where growth was 1.5x faster than other regions, despite some volume step-down due to exiting non-oncology business and load balancing.	Revenue SegmentsTotal revenue: 11% year-over-year growth. Clinical business revenue: 14% year-over-year growth. NGS revenue: 26% year-over-year growth. Nonclinical business revenue: 15% year-over-year decline. Same-store revenue (excluding Pathline): 12% year-over-year growth.

Transcript Tidbits2 rows

2026-07-28

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketNeoGenomics is expanding its menu of solid tumor testing offerings in the large, underpenetrated markets of therapy selection and MRD, with recent new product launches including the PanTracer Family and RaDaR ST. These products address a combined $33 billion market opportunity across therapy selection and MRD. The company submitted a third RaDaR ST indication to MolDX, bringing the total pending submissions to 3. If all 5 of these indications are approved, NeoGenomics would have access to over 40% of the total addressable market for tumor-informed MRD testing. The recent launch of PTEN, a new FDA-approved immunohistochemistry companion diagnostic for prostate cancer, allows the company to reach into urologic oncology, a new setting. PanTracer LBx secured MolDX reimbursement in early March, and the company is focusing on driving adoption.	About CompetitionAndrew Brackmann, the new Vice President of Investor Relations, has a deep understanding of NeoGenomics and its competitive landscape. NeoGenomics holds a leading 25% market share across hematology diagnostics and therapy selection, positioning them as a trusted provider. The company believes it has capabilities and a menu that other pure-play NGS providers don't have. Their proven model, combining a broad test menu, fast and reliable turnaround times, deep payer coverage, and workflow integration, differentiates them in the community. RaDaR ST is described as a very competitive product, able to detect down to as low as 1 part per million. The company is seeing some share gains from certain competitors with PanTracer Liquid, especially where they have a strong position within workflow and customers on the heme side.	About The Broader IndustryApproximately 80% of patients seek cancer treatment in the community setting. Community oncologists are guideline-driven and prioritize certainty, choosing partners that reduce friction and enable confident treatment decisions under operational and time pressure. Reimbursement decisions, particularly for new products like RaDaR ST, are key to driving future revenue in the diagnostics industry. The MolDX approval process and securing commercial payer contracts are critical for market access and revenue generation. NeoGenomics continues to study initiatives like PAMA, CRASH, and ACA but does not anticipate them to have a significant impact on their business in 2027.	Where Things Are HeadedNeoGenomics remains confident in its objective of driving durable and profitable growth over the near and long term. The company is raising its full year 2026 revenue guidance to a range of $802 million to $806 million. The clinical business is expected to grow in the low teens for the full year, with the NGS business projected to grow in the mid-20s. While the nonclinical business is now expected to be down high single digits year-over-year in 2026, the company remains committed to returning it to year-over-year growth in 2027. NeoGenomics anticipates approximately 100 to 150 basis points of gross margin improvement for the full year 2026 and is raising its full year 2026 adjusted EBITDA guidance to a range of $56 million to $58 million. The next-generation whole genome sequencing MRD assay remains on track, with data expected in 2027 and a potential clinical launch in 2029. The company expects more meaningful contributions from the PanTracer Family and RaDaR ST over the coming years, especially RaDaR ST with successful reimbursement wins. Benefits from Epic Aura integrations are expected to begin in 2027. Efficiency gains from the Lab of the Future program are expected to continue supporting gross margin expansion goals for the remainder of the year. Volume growth in Q3 2026 is projected to be about 1 to 1.5 points due to the impact of exiting a high-volume, low-value contract, with the mix shifting in 2027 towards mid-single-digit volume growth and softening AUP growth. G&A spend as a percentage of revenue is targeted for the low 30s this year, with hopes for it to be lower than 30% in 2027. A meaningful uptick in RaDaR ST is anticipated in 2027, with acceleration into the latter part of 2027 and 2028.	Updates On ThemeDiagnostics	Broader Themes EmergingThe 'Lab of the Future' initiative, encompassing digital pathology, AI-assisted lab automation, and instrument upgrades, indicates a broader industry trend towards technological enhancement for efficiency, scalability, and improved gross margins in laboratory operations.	Bullish-Leaning Quotes (Short)Our leading 25% market share across hematology diagnostics and therapy selection make us a trusted provider of oncology testing solutions. We're raising guidance because of these results as well as the underlying clinical strength we're seeing in the back half of this year. Our growth in NGS is proving to be durable with revenue growing 26% year-over-year. Adjusted gross margin expansion of 260 basis points year-over-year was driven primarily by strong AUP growth of 12%. Adjusted EBITDA was $14.4 million, up 36% year-over-year. The actual bookings were all-time highs for us in Q2.	Bearish-Leaning Quotes (Short)Our nonclinical business is falling short of expectations. Our Pharma business, which accounts for roughly 5% of total revenue, continues to face headwinds even as bookings increase. Pharma revenue declined 26%. We also absorbed the impact of higher freight costs and fuel surcharges. Our G&A spend as compared to some of our peer groups is definitely higher.	HiringNeoGenomics remains committed to expanding its clinical commercial organization as new products launch and gain momentum and additional RaDaR ST reimbursement approvals come through. The company remains on track to exceed 160 commercial representatives during the third quarter, and will continue to assess the size of its commercial organization over the coming years. The commercial organization has been optimized and structured around 2 dedicated ecosystems, one for pathology and one for oncology, supported by aligned marketing, medical science liaison and other teams. The company is now about equally balanced with approximately 60-plus people in each of the pathology and oncology sales teams.

2026-04-28

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketNeoGenomics reentered the MRD market with RaDaR ST, addressing a $20 billion opportunity, and is also penetrating the $13 billion therapy selection market. Submissions to MolDX for two additional RaDaR ST cancer indications, if granted, would more than double the market opportunity for the test. The company expects to cover over 45% of the $20 billion MRD market across four indications. MolDX approval for PanTracer Liquid in March led to an increase in full-year revenue guidance.	About CompetitionNeoGenomics differentiates itself from large reference labs and specialty diagnostic companies through its portfolio depth and breadth, and its relentless focus on the community setting. The company's NGS revenue grew 26%, well ahead of the overall NGS market growth rate. The payment rate for RaDaR ST is expected to follow a similar pattern to other competitors in the space, starting with Medicare and then building coverage for commercial payers.	About The Broader IndustryApproximately 80% of patients seek cancer treatment in the community setting, often an hour or more from NCI-designated cancer centers. Community oncologists prioritize certainty and guideline-driven decision-making due to large patient volumes and resource constraints. The company noted an impact from higher freight costs and fuel surcharges due to the geopolitical situation. The MolDX approval process and securing commercial payer contracts are critical for market access and revenue generation in the diagnostics industry.	Where Things Are HeadedNeoGenomics aims for consistent double-digit revenue growth, with its NGS business scaling 3 to 4 times faster than its core clinical business. The company is making targeted R&D investments in whole genome sequencing, including a next-generation MRD assay expected to launch as early as 2028. They anticipate approximately 100 basis points of gross margin expansion in 2026, driven by "Lab of the Future" initiatives like strategic sourcing, digital pathology, lab automation, and platform upgrades. The company expects its nonclinical business to see sequential growth in the second half of the year and aims to be free cash flow positive this year. Plans are underway to refinance the convertible debt in the second half of the year.	Updates On ThemeDiagnostics	Broader Themes EmergingThe integration of AI-driven algorithms is evident in the PanTracer Pro workflow, which automatically determines medically necessary add-on tests based on diagnosis, simplifying the ordering experience and improving efficiency. Strategic investments in digital pathology, lab automation, and platform upgrades are part of the "Lab of the Future" initiatives, indicating a broader industry trend towards technological enhancement for efficiency and scalability.	Bullish-Leaning Quotes (Short)We believe we're well poised to deliver consistent double-digit revenue growth. Our NGS business is scaling at a rate that is 3 to 4x faster than our core clinical business. Early insights from the RaDaR ST launch to date are very encouraging. We absolutely do think that it's sustainable. We'd be disappointed that in the midterm, this is not north of 40%. We believe the AUP is also sustainable this year. Our growth rate in the Northeast region was 1.5x faster than the other regions. I'm very excited for the year ahead as well as 2027 and beyond.	Bearish-Leaning Quotes (Short)Our nonclinical business... a decline of 15% year-over-year, primarily driven by expected softness in pharma. The decline in the gross margin in the first quarter was primarily driven by the dilutive impact of Pathline acquisition and the launch of PanTracer Liquid prior to MolDX approval. We were impacted by higher freight costs and fuel surcharges due to the geopolitical situation. We are basically trying to kind of absorb exiting this high volume, low-value contract as we kind of look into Q2 and Q3. We do not want to leave this open failure late in the game [for convert refinancing].	HiringNeoGenomics plans to add roughly 25 sales resources by the third quarter of this year to support the launch and penetration of RaDaR ST in two new indications. The company is making targeted investments in its sales and R&D functions to drive clinical test volumes and higher average unit price (AUP). The sales force is considered a productive lever for driving growth, with the company noting its sales and marketing ratio is around 13% and the oncology sales team (OSS) is in the 50s.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-07-28	NeoGenomics reported strong Q2 2026 results, exceeding revenue and adjusted EPS estimates, and returning to profitability. Robust 26% NGS revenue growth drove a positive mix shift. The company raised full-year guidance, and refinanced convertible debt. The market reacted very positively, with the stock surging over 14% (t+2 days), significantly outperforming SPY, reflecting strong confidence in the company's strategic execution and improved outlook.	Earnings Transcript	Positive	https://ir.neogenomics.com/news-releases/news-release-details/neogenomics-reports-second-quarter-2026-results	+14.10% (vs SPY: +13.27%)

Prior Earnings Metrics HistoryTable

Prior earnings scorecards